How Citigroup Could Lose $7 Billion, According to One Analyst

Joe Goldman |

CitigroupCharles Peabody of Portales Partners believes that Citigroup (C) could lose as much as $7 billion in capital due to movement in exchange rates, according to Bloomberg. Peabody claims that the dollar will continue to rise versus the yen, euro, and other currencies, which could pummel Citigroup’s earnings and its stock price. He therefore has a “sell” rating on the stock.



Citigroup has expanded its international business aggressively since 2008. As a result, Peabody believes this makes Citigroup much more vulnerable to weakness in foreign currencies than most of its rivals.

A persistent global economic slowdown, relative strength in the U.S. economy, aggressive currency depreciation policies (especially in Japan), and rumors that the Federal Reserve will begin tapering its bond-buying program are the driving forces behind this currency price movement.

However, a Citigroup spokesperson told Bloomberg that the company is strategically hedged against currency movement and is not concerned about its capital ratios. The spokesperson dismissed Peabody, claiming he had been wrong about the company’s currency exposure in 2011 and is wrong once again.

Citigroup shares lagged the baking sector on Tuesday, dropping 3.81 percent to $49.95. However, shares are up almost 80 percent for the year, meaning investors aren’t too concerned about the company’s alleged foreign currency exposure.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
C Citigroup Inc. 59.17 -0.22 -0.37 6,137,336 Trade
MYL Mylan N.V. 37.14 -0.58 -1.53 2,206,782 Trade

Comments

Emerging Growth

Pressure Biosciences Inc

Pressure BioSciences Inc is a biological life sciences research company. It is engaged in the development and commercialization of a platform technology called pressure cycling technology.

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…